Lars Bauer

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Ludwig Kappos, C. H. Polman, Mark S. Freedman et al. · Neurology · 2006 · 677 citations

Life Sciences, Neurology, Pharmacotherapy +12

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

Ludwig Kappos, Chris H. Polman, Mark S. Freedman et al. · American Journal of Ophthalmology · 2006 · 551 citations

Life Sciences, Neurology, Pharmacotherapy +12

Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study

Ludwig Kappos, Mark S. Freedman, Chris H. Polman et al. · The Lancet · 2007 · 501 citations

Life Sciences, Neurology, Neuroimmunology +9

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Ludwig Kappos, Mark S. Freedman, Chris H. Polman et al. · The Lancet Neurology · 2009 · 370 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +11

Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis

Jens Kühle, Christoph Pohl, Matthias Mehling et al. · New England Journal of Medicine · 2007 · 258 citations

Life Sciences, Neurology, Neuroscience +17